Supernus Pharmaceuticals, Inc. clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.
- Minor: SPN-812 (Viloxazine Extended-release Capsule) Primary and study completion pushed from Sep 2026 to Dec 2026
- Minor: Adults With Major Depressive Disorder Trial sites expanded: 1 → 40 locations
- Minor: SPN-817 Open-Label Extension Study · Focal Onset Seizures Trial status changed: Recruiting → Enrolling by Invitation
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1/2 | 1 | |
| Phase 2 | 4 | |
| Phase 3 | 1 | |
| Phase 4 | 1 |
Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials
Epilepsy (4) · ADHD (2) · Depression (1) · Parkinson's Disease (1)
Get alerts when Supernus Pharmaceuticals, Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.